Equity Profile

ASND

Ascendis Pharma A/S

Health CareBiotechnology$13.8B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Ascendis Pharma A/S is a biotechnology company focused on developing innovative therapies for rare diseases and endocrine disorders. Operating in the health care sector, it plays a crucial role in advancing treatment options that can significantly improve patients' lives.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ASND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+528.60%

Avg Stock Reaction

+0.76%

Last Quarter Recap

In Q1-2026, Ascendis Pharma surprised analysts with an EPS of $11.46, significantly exceeding expectations. This marked a remarkable turnaround from previous quarters, showcasing the company's potential.

Management Promises & Guidance

Focus on advancing pipeline therapies.
Commitment to addressing unmet medical needs.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, expectations are mixed as investors weigh the company's recent strong performance against potential volatility. Analysts are particularly interested in any updates regarding the pipeline and future revenue projections.

Bull Case

If Ascendis continues to deliver strong earnings and demonstrates solid pipeline progress, it could lead to increased investor confidence and stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing guidance, it could trigger a sell-off, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of their pipeline therapies?

Investors will closely scrutinize this information to gauge the company's future growth potential and market competitiveness.

How does management plan to sustain profitability following the recent EPS surprise?

Understanding the company's strategy for maintaining financial health is crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for continued strong performance in Ascendis' pipeline, especially given the recent EPS surprise.

Supporting Evidence

The company's recent turnaround suggests a shift in operational efficiency that may not be reflected in current estimates.

Options pricing indicates a significant expected move, suggesting that traders anticipate more volatility than the Street is pricing in.

Key Risk

If the company can provide strong guidance on pipeline developments, it could challenge current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Ascendis can maintain its recent momentum or if it will face challenges in sustaining growth.

Bull Confirmed If

Demonstrating continued EPS growth above $11.46 would confirm the bullish outlook.

Bear Confirmed If

Any guidance suggesting a decline in revenue or profitability could confirm the bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±9.25%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±9.3% while ASND has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

41.3%

Calls (3K)P/C Ratio: 5.70Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ascendis beats expectations, history suggests a potential average one-day move of +4.71%, confirming a strong growth narrative.

In-Line / Cautious

If results are in line but cautious, the stock may experience muted movement as investors reassess future growth prospects.

Miss

In the event of a miss, history suggests an average one-day decline of -1.60%, which could lead to increased selling pressure.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of pipeline therapies and any new data.
2Management's strategy for maintaining profitability in the coming quarters.
3Any insights into market demand for their therapies.
4Comments on operational efficiencies and cost management.
5Future guidance on revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ASND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+528.60%

Avg Stock Reaction

+0.76%

Last Quarter Recap

Management Promises & Guidance

Focus on advancing pipeline therapies.
Commitment to addressing unmet medical needs.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Bull Case

If Ascendis continues to deliver strong earnings and demonstrates solid pipeline progress, it could lead to increased investor confidence and stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing guidance, it could trigger a sell-off, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of their pipeline therapies?

Investors will closely scrutinize this information to gauge the company's future growth potential and market competitiveness.

How does management plan to sustain profitability following the recent EPS surprise?

Understanding the company's strategy for maintaining financial health is crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for continued strong performance in Ascendis' pipeline, especially given the recent EPS surprise.

Supporting Evidence

The company's recent turnaround suggests a shift in operational efficiency that may not be reflected in current estimates.

Options pricing indicates a significant expected move, suggesting that traders anticipate more volatility than the Street is pricing in.

Key Risk

If the company can provide strong guidance on pipeline developments, it could challenge current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Ascendis can maintain its recent momentum or if it will face challenges in sustaining growth.

Bull Confirmed If

Demonstrating continued EPS growth above $11.46 would confirm the bullish outlook.

Bear Confirmed If

Any guidance suggesting a decline in revenue or profitability could confirm the bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±9.25%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±9.3% while ASND has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

41.3%

Calls (3K)P/C Ratio: 5.70Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ascendis beats expectations, history suggests a potential average one-day move of +4.71%, confirming a strong growth narrative.

In-Line / Cautious

If results are in line but cautious, the stock may experience muted movement as investors reassess future growth prospects.

Miss

In the event of a miss, history suggests an average one-day decline of -1.60%, which could lead to increased selling pressure.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of pipeline therapies and any new data.
2Management's strategy for maintaining profitability in the coming quarters.
3Any insights into market demand for their therapies.
4Comments on operational efficiencies and cost management.
5Future guidance on revenue expectations.